YS-HBV-002 / YS Biopharma - LARVOL DELTA

A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | N=48 ➔ 16 | Trial completion date: May 2025 ➔ Oct 2024 | Not yet recruiting ➔ Terminated; Business strategy

Enrollment change • Trial completion date • Trial termination • Hepatitis B • Hepatology • Infectious Disease • Inflammation

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine (PRNewswire-Asia) - "YS Biopharma...announced that its YS-HBV-002 immunotherapeutic vaccine, designed to treat patients suffering from chronic hepatitis B virus ('HBV') infection, has been granted clinical trial approval by the Philippine Food and Drug Administration ('PFDA'). In light of the approval, the Company is preparing to initiate a Phase I clinical trial for YS-HBV-002 in the Philippines, which is expected to begin in June 2024....This trial will employ a double-blind, randomized, placebo-controlled, dose-escalation approach, and aims to evaluate the safety, immunogenicity, and efficacy of YS-HBV-002 among adult patients diagnosed with chronic HBV infection."

Trial status • Hepatitis B • Infectious Disease

A Phase I, The Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Trial completion date: Jul 2024 ➔ May 2025 | Initiation date: Feb 2024 ➔ May 2024 | Trial primary completion date: May 2024 ➔ Sep 2024

Trial completion date • Trial initiation date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Phase I, The Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd.

New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection (PRNewswire-Asia) - "YS Biopharma...announced that the United States Patent and Trademark Office has issued it a patent covering the Company's PIKA YS-HBV-002, an immunotherapeutic vaccine designed to treat patients suffering from chronic hepatitis B virus ('HBV') infection. YS Biopharma expects to submit an Investigational New Drug (IND) application and commence the clinical development of PIKA YS-HBV-002 as a novel immunotherapy for the treatment of chronic HBV infection in 2024."

IND • Patent • Hepatitis B